Asian technology companies account for a third of regional investment indices, but the ban on advanced chips is testing appetite for a sector already facing cyclical weakness and ongoing regulatory uncertainty.
Minority shareholders risk losing out as Sinovac and Hollysys refuse to accept buyout offers. But, seemingly unfazed by the prospect of delisting, will the firms pursue value creation elsewhere?